Search

Displaying results 1501 - 1510 of 10000 in total
  1. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: One-A-day Advance Men's, One Tablet Daily Mens FormulaCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.

    Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds with 4 or More Rings
  3. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [ribavirin] depending on the level of liver damage or cirrhosis [FDA Label]. … SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma

    Categories: Antivirals for treatment of HCV infections
  4. Drug

    Propylene glycol

    go.drugbank.com/drugs/DB01839
    ApprovedInvestigational

    A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.

    Mixtures: Dg Lubricant Eye Drops, DG Lubricant Eye DropsCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements … It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.

    Categories: combinations of sulfonamides
  6. Drug

    Testosterone enanthate

    go.drugbank.com/drugs/DB13944
    ApprovedInvestigational

    [A31615] This testosterone derivative was first approved on December 24, 1953.[L8941] In 2017, about 6.5 million retail prescriptions for testosterone therapy were filled [L4659]. … Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate.

  7. Drug

    Tazobactam

    go.drugbank.com/drugs/DB01606
    ApprovedInvestigational

    It is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections. … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.

    Mixtures: Zosyn in Galaxy Containers, Zosyn in Galaxy Containers
  8. Drug

    Propiomazine

    go.drugbank.com/drugs/DB00777
    Approved

    Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. … Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia.

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. … [L939] It is the first treatment made available in the United States for Chagas disease.

  10. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects … [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    Categories: CD22 (Clusters of Differentiation 22) inhibitors